Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Conditions Studied

Interventions

  • OTHER Non-Interventional

Study Locations (20)

Illinois

  • Northwestern University — Chicago
  • Rush University Medical Group — Chicago
  • The University of Chicago — Chicago
  • Loyola University Medical Center — Maywood

Florida

  • Mayo Clinic Jacksonville — Jacksonville
  • AdventHealth Orlando — Orlando
  • Moffit Cancer Center — Orlando

California

  • City of Hope — Duarte
  • USC Norris Comprehensive Cancer Center — Los Angeles

Georgia

  • Emory University — Atlanta
  • Georgia Cancer Center — Augusta

Alabama

  • University of Alabama Birmingham — Birmingham

Arizona

  • Mayo Clinic Arizona — Phoenix

Colorado

  • University of Colorado — Aurora

Kansas

  • The University of Kansas Clinical Research Center — Fairway

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2023-08-01
Est. Completion 2027-10-15

Sponsor

Incyte Corporation

163 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05919511

The ClinicalTrials.gov registry entry for NCT05919511 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 163 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with cGVHD appearing as the primary indexed condition, and to 1 intervention — of which Non-Interventional is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05919511 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Illinois, Florida, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05919511 about?

NCT05919511 is a clinical study titled "Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease". The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

What is the current status of trial NCT05919511?

This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2023-08-01. Estimated completion is 2027-10-15.

What conditions does trial NCT05919511 study?

This clinical trial studies the following conditions: cGVHD. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05919511?

The interventions under investigation include: Non-Interventional (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05919511?

This trial is sponsored by Incyte Corporation, which has 163 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05919511 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial